Immunology for
a Better Future
Learn More
Advancing Therapeutic
Solutions
Our lead program, Ampligen®, is an immuno-modulator that has shown broad spectrum activity in in-vitro and animal testing and is being evaluated in clinical studies for a range of debilitating and life-threatening conditions.
Learn More
Focused on Improving
Lives
We are working to develop solutions that have the potential to help patients across a number of disease areas, including oncology, immune disorders and viral diseases.
Learn More
Key Highlights
AIM ImmunoTech Bolsters Board of Directors with Appointment of Pharmaceutical Industry Veteran Nancy K. Bryan, with Deep Commercial, Marketing, Business Development and Corporate Finance Expertise
OCALA, Fla., March 30, 2023 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases - including...
AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast
OCALA, Fla., March 27, 2023 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases - including...
AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease
Growing body of data supports Ampligen's potential as both a prophylactic and an early-onset therapy against human Ebola virus disease outbreaksOCALA, Fla., March 16, 2023 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), an immuno-pharma company...